HMAs have been found to upregulate the expression of PD-1, PD-L1, PD-L2, and CTLA4 in patients with AML and MDS, which is thought to be one of the mechanisms of HMA resistance [33]. This evidence concerns the gene CD274 and acute myeloid leukemia.